MHRA Ramps Up Facility Inspections, Sees Spike in Critical Findings for Second Straight Year

During a one-year period, the UK’s Medicines & Healthcare products Regulatory Agency conducted 47 inspections of pharma companies, during which they uncovered 27 critical findings, 169 major and 155 minor findings, according to a report.

From April 1, 2014 to March 31, 2015, the MHRA inspected 25 innovative pharmaceutical companies, 20 generic drugmakers and two orphan, niche or herbal product makers, the internal report shows.

Of the critical findings, 17 went to generics companies and 10 went to innovative drugmakers. The most cited critical finding was a lack of reference safety information, followed by signal management failures, oversight and quality system failures and risk management system lapses, according to the document.

Sharp Increases

The agency reported a “sharp increase” in the number of critical findings associated with signal management. Seven critical findings were reported that were associated with failures to conduct signal detection activities, failures to incorporate all available data into signal detection activities, significant delays in completing signal evaluation and failures to address previously reported major inspection findings.

Less-cited critical findings included system failures, Periodic Safety Update Report production issues, individual case safety report management problems and submission of false and misleading information.

The 27 critical findings are up from 19 found during the April 2013 to March 2014 period, the report shows. The year prior had 18 critical findings.

Of the 169 major findings, signal management and individual case safety report management concerns were the top two findings, followed by quality systems issues and reference safety information.

The MHRA said that 15 of the inspections were of marketing authorization holders that had not previously undergone an MHRA inspection. Twenty one inspections were routine re-inspections and 10 inspections were trigged due to critical findings identified at previous inspections or in response to a specific issue.

Further, two inspections were requested by the European Committee for Medicinal Products for Human Use and 20 of those inspections were performed to fulfill the EMA’s program of inspections relating to centrally authorized products.

To read the MHRA’s inspection report, go to — Kellen Owings


$895 $695


Subscribe to International Pharmaceutical Regulatory Monitor and save $200 off the regular one-year price of $895 — plus receive a FREE CD copy of our webinar Pharmacovigilance in the EU — a $287 Value!

Key Benefits

LINKS TO KEY DOCUMENTS — Each issue provides English-language texts of important, hard to obtain proposals, regulations, guidelines and other documents.

FDANEWS DRUG DAILY BULLETIN — This daily email brings you important FDA and international regulatory, legislative and business news in the pharmaceutical industry.

ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.